Ignite Creation Date:
2024-05-06 @ 3:59 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04837040
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-10
First Post:
2021-04-06
Brief Title:
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
Sponsor:
Crinetics Pharmaceuticals Inc
Organization:
Crinetics Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands PATHFNDR-1
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PATHFNDR-1
Brief Summary:
A randomized placebo-controlled study designed to evaluate the safety and efficacy of paltusotine also known as CRN00808 an orally administered nonpeptide somatostatin agonist in subjects with acromegaly previously treated with somatostatin receptor ligand SRL based treatment regimens
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-005431-70 | EUDRACT_NUMBER | None | None |